Milestone Scientific (MLSS)
Market Price (2/15/2026): $0.2617 | Market Cap: $21.5 MilSector: Health Care | Industry: Health Care Equipment
Milestone Scientific (MLSS)
Market Price (2/15/2026): $0.2617Market Cap: $21.5 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -42% | Weak multi-year price returns2Y Excs Rtn is -95%, 3Y Excs Rtn is -129% | Penny stockMkt Price is 0.3 |
| Megatrend and thematic driversMegatrends include Precision Medicine, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -75% | |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.6%, Rev Chg QQuarterly Revenue Change % is -6.1% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -47%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -47% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -35% | ||
| Key risksMLSS key risks include [1] financial instability, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -42% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -95%, 3Y Excs Rtn is -129% |
| Penny stockMkt Price is 0.3 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -75% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.6%, Rev Chg QQuarterly Revenue Change % is -6.1% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -47%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -47% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -35% |
| Key risksMLSS key risks include [1] financial instability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. NYSE American Non-Compliance and Delisting Risk: Milestone Scientific received a notice from NYSE American on October 14, 2025, stating non-compliance with listing standards due to insufficient stockholders' equity and consistent losses over the five most recent fiscal years. The company was required to submit a compliance plan by November 7, 2025, and demonstrate compliance by April 8, 2027, indicating a significant risk to its continued listing and investor confidence.
2. Persistent Unprofitability and Weak Financials: The company consistently demonstrated unprofitability during the period, reporting an operating loss of $(1.1) million and a net loss of $(1.2) million, or $(0.01) per share, in Q3 2025, despite some revenue stability and operating expense reductions. Milestone Scientific also recorded a negative profit margin of -74.7%, an operating margin of -48.1%, and a return on equity of -136.5% for the trailing twelve months, reflecting ongoing financial challenges in achieving sustainable profitability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -37.1% change in MLSS stock from 10/31/2025 to 2/14/2026 was primarily driven by a -35.8% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.42 | 0.26 | -37.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | -1.7% |
| P/S Multiple | 3.8 | 2.4 | -35.8% |
| Shares Outstanding (Mil) | 82 | 82 | -0.3% |
| Cumulative Contribution | -37.1% |
Market Drivers
10/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| MLSS | -37.1% | |
| Market (SPY) | -0.0% | 9.9% |
| Sector (XLV) | 9.3% | -15.5% |
Fundamental Drivers
The -45.1% change in MLSS stock from 7/31/2025 to 2/14/2026 was primarily driven by a -46.8% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.48 | 0.26 | -45.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | 3.7% |
| P/S Multiple | 4.6 | 2.4 | -46.8% |
| Shares Outstanding (Mil) | 82 | 82 | -0.6% |
| Cumulative Contribution | -45.1% |
Market Drivers
7/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| MLSS | -45.1% | |
| Market (SPY) | 8.2% | 24.0% |
| Sector (XLV) | 21.4% | 0.3% |
Fundamental Drivers
The -79.0% change in MLSS stock from 1/31/2025 to 2/14/2026 was primarily driven by a -78.6% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.26 | 0.26 | -79.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | 0.6% |
| P/S Multiple | 11.4 | 2.4 | -78.6% |
| Shares Outstanding (Mil) | 80 | 82 | -2.9% |
| Cumulative Contribution | -79.0% |
Market Drivers
1/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| MLSS | -79.0% | |
| Market (SPY) | 14.3% | 25.0% |
| Sector (XLV) | 8.8% | 5.6% |
Fundamental Drivers
The -60.4% change in MLSS stock from 1/31/2023 to 2/14/2026 was primarily driven by a -51.5% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.67 | 0.26 | -60.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | -5.1% |
| P/S Multiple | 5.0 | 2.4 | -51.5% |
| Shares Outstanding (Mil) | 71 | 82 | -13.8% |
| Cumulative Contribution | -60.4% |
Market Drivers
1/31/2023 to 2/14/2026| Return | Correlation | |
|---|---|---|
| MLSS | -60.4% | |
| Market (SPY) | 74.0% | 17.7% |
| Sector (XLV) | 23.7% | 6.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MLSS Return | -3% | -77% | 44% | 39% | -72% | -4% | -88% |
| Peers Return | 6% | -24% | -14% | -9% | -15% | 13% | -39% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| MLSS Win Rate | 50% | 33% | 42% | 42% | 25% | 50% | |
| Peers Win Rate | 43% | 42% | 47% | 43% | 40% | 80% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MLSS Max Drawdown | -28% | -80% | 0% | -22% | -72% | -7% | |
| Peers Max Drawdown | -13% | -35% | -29% | -28% | -33% | -3% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: XRAY, NVST, BDX, ICUI, AVNS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | MLSS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -91.0% | -25.4% |
| % Gain to Breakeven | 1016.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -64.1% | -33.9% |
| % Gain to Breakeven | 178.5% | 51.3% |
| Time to Breakeven | 69 days | 148 days |
| 2018 Correction | ||
| % Loss | -83.2% | -19.8% |
| % Gain to Breakeven | 496.5% | 24.7% |
| Time to Breakeven | 382 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -94.5% | -56.8% |
| % Gain to Breakeven | 1710.0% | 131.3% |
| Time to Breakeven | 2,382 days | 1,480 days |
Compare to XRAY, NVST, BDX, ICUI, AVNS
In The Past
Milestone Scientific's stock fell -91.0% during the 2022 Inflation Shock from a high on 3/10/2021. A -91.0% loss requires a 1016.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Milestone Scientific (MLSS)
AI Analysis | Feedback
Here are 1-2 brief analogies for Milestone Scientific (MLSS):
- Intuitive Surgical (ISRG) for precision injections: Like Intuitive Surgical brought robotic precision to surgery with the Da Vinci system, Milestone Scientific brings computer-controlled precision to medical and dental injections, making them more accurate and comfortable.
- Tesla for anesthesia delivery: Just as Tesla innovated and disrupted the traditional automotive industry, Milestone Scientific aims to technologically innovate and improve the traditional, often painful and imprecise, methods of delivering anesthesia and other injections.
AI Analysis | Feedback
- The Wand STA System: A computer-controlled local anesthetic delivery system designed to provide virtually pain-free dental injections.
- CompuFlo Epidural System: A computer-controlled instrument that assists anesthesiologists in performing epidural procedures with enhanced precision and safety.
- Disposable Handpieces and Cartridges: Single-use accessories, including needle-tipped handpieces and anesthetic cartridges, specifically designed for use with their delivery systems.
AI Analysis | Feedback
Milestone Scientific (MLSS) sells its dental and medical devices primarily to other companies, specifically through a network of distributors. These distributors, in turn, sell the products to dental practices, hospitals, and pain management clinics.
Based on their latest financial reports, their major distribution partners, which serve as their primary customers, include:
- For Dental Products:
- Henry Schein, Inc. (Symbol: HSIC)
- Patterson Companies, Inc. (Symbol: PDCO)
- Benco Dental Company (Private Company)
- For Medical Products:
- Medline Industries (Private Company)
- Thermo Fisher Scientific, Inc. (via its Fisher Healthcare division) (Symbol: TMO)
- Owens & Minor, Inc. (Symbol: OMI)
- McKesson Corporation (Symbol: MCK)
These companies act as Milestone Scientific's major customers by facilitating the distribution of their products to the ultimate end-users in the healthcare industry.
AI Analysis | Feedback
nullAI Analysis | Feedback
Eric C. Hines, Chief Executive Officer
Mr. Hines was appointed CEO of Milestone Scientific in August 2025. He brings over 25 years of leadership experience in scaling sales-driven enterprise software companies, with a background in healthcare and customer experience management. Most recently, he served as President of North America at Ex Libris, a division of Clarivate Plc, where he led operations across the U.S., Canada, and Latin America, increasing annual revenue from approximately $50 million to over $100 million. At Ex Libris, he launched multiple new product lines and managed marketing, sales, and service organizations. Earlier in his career, Mr. Hines held executive positions at NICE Systems, leading an over $90 million North American security business and overseeing customer experience management.
Keisha Harcum, Vice President of Finance and Controller
Ms. Harcum has served as Vice President of Finance and Controller at Milestone Scientific Inc. since December 2014. She is an accomplished finance professional with extensive experience in financial management and accounting. Prior to joining Milestone Scientific, Ms. Harcum worked as an Accounting Manager at Innovative Educational Programs, LLC from February 2007 to December 2013, where she was responsible for managing accounting functions.
Jason Papes, Senior Vice President, Global Head of Sales and Marketing
Mr. Papes was appointed Senior Vice President, Global Head of Sales and Marketing for Milestone Scientific in August 2025. He brings over 30 years of experience in sales, marketing, and business development within the healthcare industry. His background includes leadership roles at large-cap medical technology companies and successful entrepreneurial ventures across orthopedics, neurology, pain management, and digital imaging. Most recently, Mr. Papes served as Founder and Managing Partner of TEN20 Medical Distribution, a healthcare sales organization focused on spinal implants and clinical research, which became one of the largest distributorships for Orthofix's bone growth stimulators and bone graft products, earning multiple Distributor of the Year honors. He also led several affiliated ventures through successful exits, including Neuro-Pro Monitoring and TEN20 Living Assistance. Prior to founding TEN20, Mr. Papes held executive positions at Stryker Imaging, where he led a $30 million commercial expansion across North America, and at Brainlab, where he significantly grew U.S. market share in surgical navigation and helped establish U.S. operations.
Leonard A. Osser, Founder & Vice Chairman
Mr. Osser founded Milestone Scientific in 1989 and has been a director since its inception. He served as Chief Executive Officer of Milestone Scientific from its founding until 2021, and as Chairman of Milestone Scientific from 1991 until September 2009. Mr. Osser is the Managing Member of U.S. Asian Consulting Group, LLC, a New Jersey-based provider of consulting services specializing in distressed or turnaround situations in both the public and private markets. He also serves as a special consultant to the board of directors of Nexalin Technology, Inc.
Jan Adriaan (Arjan) Haverhals, Director
Mr. Haverhals served as Milestone Scientific's Chief Executive Officer and President until his retirement from the officer role on December 31, 2024, but continues to serve as a director and consultant. He was also President and CEO of Milestone Scientific's Dental Division, Wand Dental Inc., since June 2020. He brings more than 30 years of sales, marketing, product development, and international expansion experience within the medical device, pharmaceutical, and other industries. Prior to joining Milestone Scientific, Mr. Haverhals was Senior Vice President of Sales at Xcentric Mold & Engineering. He also held a series of senior sales and marketing roles at Straumann, LLC, a global leader in manufacturing medical and dental devices, where he oversaw product franchises and led the launch of over 30 products, and served as Senior Vice President of Global Sales Digital Solutions, which included oversight of the strategic acquisition of Etkon. His earlier career includes roles as Vice President of Global Marketing & Sales at Elkem AS and Executive Vice President of Marketing & Sales at Cresco Ti Systems SÃ rl, a global dental implant company, where he was responsible for turning around and managing global sales, marketing, and international business and achieved over 100% return on investment for shareholders.
AI Analysis | Feedback
The key risks to Milestone Scientific (MLSS) are:
- Financial Instability and Liquidity: Milestone Scientific has consistently reported operating losses and negative net margins, indicating a lack of profitability. The company is "quickly burning through cash," a critical factor for investors to monitor given its current market capitalization. Furthermore, Milestone Scientific received a notice from NYSE American regarding non-compliance with listing standards, highlighting its financial precariousness. The stock has also experienced a significant decline year-to-date and is considered "high risk" due to its volatility.
- Market Adoption, Commercialization, and Competition: The company faces challenges in successfully commercializing its products and executing its growth strategies. Milestone Scientific terminated its U.S. distribution agreement with Henry Schein in December 2022, transitioning to a model with multiple non-exclusive distributors and an e-commerce platform. This change in marketing and distribution channels carries risks of interruption to marketing efforts and the success of building new channels. While the company is implementing initiatives to accelerate growth, including expanding sales programs and digital marketing, the success of these efforts is crucial for improved financial performance. The medical equipment industry in which Milestone Scientific operates is competitive, with several alternative companies.
- Intellectual Property Dependence and Litigation Risk: Milestone Scientific's business relies heavily on its patented technologies, such as C-CLAD and Dynamic Pressure Sensing (DPS) systems, which are central to its product offerings for painless and precise injections. While the company has secured numerous patents and received recent notices of allowance for new patent applications, "adverse patent rulings" are explicitly cited as a risk that could materially affect actual results.
AI Analysis | Feedback
nullAI Analysis | Feedback
Milestone Scientific (MLSS) operates in two primary segments: dental and medical, offering innovative injection technologies.
Dental Segment
Milestone Scientific's main product in the dental segment is the Single Tooth Anesthesia (STA) System, also known as The Wand or CompuDent System. This computer-controlled local anesthetic delivery system aims to provide virtually painless injections.
- The global total addressable market for the SingleTooth Anesthesia product is estimated to be approximately $1.309 billion, based on 436,409 dentists in the developed world.
- More broadly, the global dental anesthetics market is valued at approximately $1.73 billion in 2025 and is projected to reach $2.24 billion by 2030. North America accounted for 42.13% of this revenue in 2024.
Medical Segment
In the medical segment, Milestone Scientific offers the CompuFlo Epidural System, a computer-controlled drug delivery system for epidural procedures, and CompuMed for various other medical applications.
- An estimated 4-5 million epidural anesthesia procedures are performed annually, indicating a significant addressable market for the CompuFlo Epidural System. While the specific region for this figure is not explicitly stated, the context suggests a global perspective, with recent regulatory approval in Brazil and Medicare reimbursement in multiple U.S. states expanding its market. The company is expanding its reach within the U.S. pain management market through partnerships and Medicare approvals, targeting pain management clinics, ambulatory surgery centers, and federal healthcare systems.
Overall, a combined total addressable market for Milestone Scientific's products (dental and medical) was estimated at approximately $4 billion in 2023.
AI Analysis | Feedback
Milestone Scientific (MLSS) is poised for future revenue growth over the next 2-3 years, driven by several key initiatives and market developments:
-
Expanded Adoption and Reimbursement for CompuFlo® Epidural System: The CompuFlo® Epidural System is a significant driver, with Milestone Scientific actively expanding its commercial rollout across pain management clinics and ambulatory surgery centers. Key to this expansion is the securing of Medicare Part B physician payment rate assignment in multiple U.S. states, which enhances market accessibility and financial viability for medical professionals using the system. The company is also pursuing additional Medicare Administrative Contractor (MAC) coverage and has entered into strategic partnerships, such as with Axial Biologics, to accelerate adoption. Growing international interest in CompuFlo® further contributes to its potential. An uptick in recurring revenue from CompuFlo® disposables has also been observed, indicating increased utilization of the system.
-
Growth in the Dental Division through Direct Sales and International Expansion: Milestone Scientific's dental division, particularly its international sales, has demonstrated strong growth, with international dental sales increasing significantly year-over-year. Domestically, the company's strategic shift to an e-commerce sales model for its dental products, like the STA® Single Tooth Anesthesia System, has proven successful in strengthening gross margins and driving U.S. dental revenue. The company is also focusing on expanding North American dental sales programs, increasing direct sales opportunities, and enhancing digital marketing efforts to boost brand awareness, alongside securing new international registrations for the STA® system.
-
Strategic Initiatives Under New Leadership: Under the leadership of new CEO Eric Hines, appointed in August 2025, Milestone Scientific is implementing comprehensive strategic initiatives designed to accelerate growth and improve operational efficiency. These initiatives include a guided relaunch and refined reimbursement strategy for the CompuFlo® Epidural System in medical markets, as well as strengthening the overall sales infrastructure and optimizing operations across both medical and dental segments.
-
Increasing Recurring Revenue from Disposables: As the installed base of both the CompuFlo® Epidural System and STA® Single Tooth Anesthesia System grows, Milestone Scientific expects to see an increase in recurring revenue from the sales of associated disposable products. The company has already noted an uptick in recurring revenue from CompuFlo® disposables, which is a positive indicator of sustained product usage and a stable revenue stream.
AI Analysis | Feedback
Share Issuance
- Milestone Scientific's shares outstanding have generally increased over the last five years, from 65.81 million in 2020 to 82.04 million as of October 2025.
- In Q1 2025, the company secured $800,000 in convertible financing from members of its Board of Directors.
Inbound Investments
- In the first quarter of 2025, Milestone Scientific obtained $800,000 in convertible funding from its Board of Directors.
Capital Expenditures
- Milestone Scientific's capital expenditures were reported as -10, -5, -9, -15, and -21 over various periods in recent financial statements, indicating relatively low spending in this area.
- The company is focusing on broad-based reductions in operating expenses and investments in market analysis and reimbursement strategies.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 21.93 |
| Mkt Cap | 3.1 |
| Rev LTM | 2,520 |
| Op Inc LTM | 182 |
| FCF LTM | 77 |
| FCF 3Y Avg | 145 |
| CFO LTM | 190 |
| CFO 3Y Avg | 229 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.6% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | -1.7% |
| QoQ Delta Rev Chg LTM | -0.4% |
| Op Mgn LTM | 6.0% |
| Op Mgn 3Y Avg | 5.2% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 8.5% |
| CFO/Rev 3Y Avg | 10.0% |
| FCF/Rev LTM | 5.6% |
| FCF/Rev 3Y Avg | 6.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.1 |
| P/S | 1.6 |
| P/EBIT | 9.0 |
| P/E | -2.2 |
| P/CFO | 13.2 |
| Total Yield | -15.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 4.8% |
| D/E | 0.4 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.8% |
| 3M Rtn | 15.5% |
| 6M Rtn | 7.9% |
| 12M Rtn | -15.1% |
| 3Y Rtn | -39.4% |
| 1M Excs Rtn | 2.5% |
| 3M Excs Rtn | 12.9% |
| 6M Excs Rtn | 7.0% |
| 12M Excs Rtn | -28.0% |
| 3Y Excs Rtn | -106.5% |
Price Behavior
| Market Price | $0.26 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/03/1995 | |
| Distance from 52W High | -78.2% | |
| 50 Days | 200 Days | |
| DMA Price | $0.30 | $0.54 |
| DMA Trend | down | down |
| Distance from DMA | -12.0% | -51.5% |
| 3M | 1YR | |
| Volatility | 66.8% | 82.0% |
| Downside Capture | 257.90 | 224.36 |
| Upside Capture | 110.65 | 39.95 |
| Correlation (SPY) | 11.1% | 24.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.25 | -0.76 | 0.43 | 1.60 | 1.05 | 0.91 |
| Up Beta | -9.52 | -11.47 | -4.82 | 2.37 | 0.77 | 0.73 |
| Down Beta | 0.40 | -1.01 | -0.73 | 0.83 | 1.12 | 1.27 |
| Up Capture | 256% | 106% | 102% | 78% | 23% | 26% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 19 | 25 | 47 | 97 | 328 |
| Down Capture | 259% | 206% | 302% | 218% | 149% | 103% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 22 | 36 | 77 | 148 | 401 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MLSS | |
|---|---|---|---|---|
| MLSS | -79.2% | 81.5% | -1.58 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 6.1% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 25.4% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | 5.5% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | 14.0% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 11.7% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 28.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MLSS | |
|---|---|---|---|---|
| MLSS | -41.3% | 84.3% | -0.26 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 11.9% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 22.7% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 7.4% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 7.8% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 15.1% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MLSS | |
|---|---|---|---|---|
| MLSS | -17.5% | 87.2% | 0.18 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 11.2% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 18.2% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 4.0% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 7.2% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 14.1% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 7.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.45 | 14,427 | 6,488 | 4,081,821 | Form | |
| 2 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.43 | 80,000 | 34,416 | 3,870,408 | Form | |
| 3 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.44 | 100,000 | 43,980 | 3,912,797 | Form | |
| 4 | Bp4, S.r.l. | Direct | Sell | 10232025 | 0.45 | 24,034 | 10,880 | 4,133,691 | Form | |
| 5 | Bp4, S.r.l. | Direct | Sell | 10232025 | 0.44 | 40,000 | 17,592 | 3,998,306 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.